Literature DB >> 8005215

Epidemiology of Staphylococcus aureus in patients with cystic fibrosis.

C Branger1, J M Fournier, J Loulergue, A Bouvet, P Goullet, A Boutonnier, C de Gialluly, G Couetdic, M Chomarat, M C Jaffar-Banjee.   

Abstract

Seven hundred and thirty-four isolates of Staphylococcus aureus, recovered from the sputum of 238 cystic fibrosis patients in six French hospitals, were characterized by esterase electrophoretic typing, capsular polysaccharide serotyping and phage typing and tested against 14 antibiotics for sensitivity. Thirty-four esterase electrophoretic types were found with a genotypic diversity coefficient of 0.91. Five hundred and forty-eight (78.7%) isolates produced capsular polysaccharide and 350 (50.3%) were type 8. Four hundred and sixty isolates (66.6%) were phage typable and 202 (28.2%) were lysed by group III bacteriophages. No esterase electrophoretic type, capsular type or phage type was specific to cystic fibrosis. Isolates belonged to a wide range of types, similar to strains acquired outside hospitals. Eighty-five patients had three or more consecutive isolates over at least 6 months. The ability of S. aureus to persist for long periods of time has been demonstrated in 73% of them. Methicillin-resistance was encountered among 73 strains (9.8%) which were also multiresistant. Two hundred and eighty-nine (39.9%) strains were sensitive to all antibiotics tested except to penicillin. Pristinamycin and co-trimoxazole were the most effective antibiotics. These results could contribute to the elaboration of a rational approach to the prophylaxis and therapy of respiratory staphylococcal infections in cystic fibrosis patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005215      PMCID: PMC2271499          DOI: 10.1017/s0950268800051190

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  23 in total

1.  Estimation of average heterozygosity and genetic distance from a small number of individuals.

Authors:  M Nei
Journal:  Genetics       Date:  1978-07       Impact factor: 4.562

Review 2.  Pulmonary infection in cystic fibrosis.

Authors:  P A Friend
Journal:  J Infect       Date:  1986-07       Impact factor: 6.072

3.  Selection of antibiotics for treatment and prophylaxis of staphylococcal infections in cystic fibrosis patients.

Authors:  A Bauernfeind; B Przyklenk; C Matthias; R Jungwirth; R M Bertele; K Harms
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

4.  Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types.

Authors:  D Sompolinsky; Z Samra; W W Karakawa; W F Vann; R Schneerson; Z Malik
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

5.  An esterase zymogram of Escherichia coli.

Authors:  P Goullet
Journal:  J Gen Microbiol       Date:  1973-07

6.  Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis.

Authors:  N Hoiby
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1974-08

7.  Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships.

Authors:  C Schlichting; C Branger; J M Fournier; W Witte; A Boutonnier; C Wolz; P Goullet; G Döring
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

8.  Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis.

Authors:  A Albus; J M Fournier; C Wolz; A Boutonnier; M Ranke; N Høiby; H Hochkeppel; G Döring
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

9.  Direct testing of blood culture for detection of the serotype 5 and 8 capsular polysaccharides of Staphylococcus aureus.

Authors:  A Boutonnier; F Nato; A Bouvet; L Lebrun; A Audurier; J C Mazie; J M Fournier
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

10.  Antimicrobial chemotherapy in patients with cystic fibrosis.

Authors:  J P Guggenbichler; J Schneeberger
Journal:  Infection       Date:  1987       Impact factor: 3.553

View more
  7 in total

1.  Genetic relationship between methicillin-sensitive and methicillin-resistant Staphylococcus aureus strains from France and from international sources: delineation of genomic groups.

Authors:  Catherine Branger; Carole Gardye; Jacques-Olivier Galdbart; Catherine Deschamps; Nicole Lambert
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

2.  Regulation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides by CO(2).

Authors:  S Herbert; S W Newell; C Lee; K P Wieland; B Dassy; J M Fournier; C Wolz; G Döring
Journal:  J Bacteriol       Date:  2001-08       Impact factor: 3.490

3.  Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis.

Authors:  L S Miall; N T McGinley; K G Brownlee; S P Conway
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

4.  Characterization of five esterases from Listeria monocytogenes and use of their electrophoretic polymorphism for strain typing.

Authors:  P Gilot; P Andre
Journal:  Appl Environ Microbiol       Date:  1995-04       Impact factor: 4.792

5.  Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients.

Authors:  V Cafiso; T Bertuccio; D Spina; F Campanile; D Bongiorno; M Santagati; A Sciacca; C Sciuto; S Stefani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-04       Impact factor: 3.267

6.  Characterization of Listeria monocytogenes isolates by esterase electrophoresis.

Authors:  J Harvey; A Gilmour
Journal:  Appl Environ Microbiol       Date:  1996-04       Impact factor: 4.792

7.  Superantigen types in Staphylococcus aureus isolated from patients with cystic fibrosis.

Authors:  J Bania; A Dabrowska; B Rózalska; B Sadowska; M Wieckowska-Szakiel; K Korzekwa; A Zarczyńska; J Bystroń; J Chrzanowska; J Molenda
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.